Repository logo
 
Publication

Cannabidiol and terpene formulation reducing SARS-CoV-2 infectivity tackling a therapeutic strategy

2022-02-15Journal article Open access
Simple item page
dc.contributor.authorSantos, Susana
dc.contributor.authorBarata, Pedro
dc.contributor.authorCharmier, Adilia
dc.contributor.authorLehmann, Inês
dc.contributor.authorRodrigues, Suzilaine
dc.contributor.authorMelosini, Matteo M.
dc.contributor.authorPais, Patrick J.
dc.contributor.authorSousa, André P.
dc.contributor.authorTeixeira, Catarina
dc.contributor.authorSantos, Inês
dc.contributor.authorRocha, Ana Catarina
dc.contributor.authorBaylina, Pilar
dc.contributor.authorFernandes, Ruben
dc.date.accessioned2024-04-08T13:49:57Z
dc.date.available2024-04-08T13:49:57Z
dc.date.issued2022-02-15
dc.description.abstractIn late 2019, COVID-19 emerged in Wuhan, China. Currently, it is an ongoing global health threat stressing the need for therapeutic compounds. Linking the virus life cycle and its interaction with cell receptors and internal cellular machinery is key to developing therapies based on the control of infectivity and inflammation. In this framework, we evaluate the combination of cannabidiol (CBD), as an anti-inflammatory molecule, and terpenes, by their anti-microbiological properties, in reducing SARS-CoV-2 infectivity. Our group settled six formulations combining CBD and terpenes purified from Cannabis sativa L, Origanum vulgare, and Thymus mastichina. The formulations were analyzed by HPLC and GC-MS and evaluated for virucide and antiviral potential by in vitro studies in alveolar basal epithelial, colon, kidney, and keratinocyte human cell lines.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSantos, S., Barata, P., Charmier, A., Lehmann, I., Rodrigues, S., Melosini, M. M., Pais, P. J., Sousa, A. P., Teixeira, C., Santos, I., Rocha, A. C., Baylina, P., & Fernandes, R. (2022). Cannabidiol and terpene formulation reducing SARS-CoV-2 infectivity tackling a therapeutic strategy. Frontiers in Immunology, 13, 1–12. https://doi.org/10.3389/fimmu.2022.841459pt_PT
dc.identifier.doi10.3389/fimmu.2022.841459pt_PT
dc.identifier.eissn1664-3224
dc.identifier.urihttp://hdl.handle.net/10400.22/25297
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relationThis research was partially funded by the European Commission, European Regional Development, FEDER/02/SAICT/2020/072560 SI-B7-2020-15, POCI-01-02B7-FEDER-053456, BIOBLOCKCOVID. The funding allowed to perform the collection and harvesting of the medicinal plants, extract and purify the terpenes and formulations, execute the formulations, and execute preliminary assays related to toxicity. Considering in vitro virucide assays and gene expression assays, the work was partially funded by FCT – Fundação para a Ciência e Tecnologia (REF UID/BIM/04293/2019) and was partially supported by grants 104 and 112 of the 1st edition of RESEARCH4COVID (FCT) and by the grant 418 from the 2nd edition of RESEARCH4COVID-19 (FCT). This work was also partially supported by FEDER-European Regional Development Fund with the grant FEDER/02/SAICT/2020/072560.pt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.841459/fullpt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCBD - cannabidiolpt_PT
dc.subjectEndocannabinoid system (ECS)pt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectTherapeuticspt_PT
dc.subjectTerpenespt_PT
dc.subjectFormulationspt_PT
dc.subjectEssential oil (EO)pt_PT
dc.titleCannabidiol and terpene formulation reducing SARS-CoV-2 infectivity tackling a therapeutic strategypt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage12pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleFrontiers in Immunologypt_PT
oaire.citation.volume13pt_PT
person.familyNameBAYLINA MACHADO
person.givenNamePILAR
person.identifier.ciencia-id1419-F23D-4920
person.identifier.orcid0000-0002-3740-862X
person.identifier.ridB-5134-2010
person.identifier.scopus-author-id56534079700
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationb1482a24-d9d8-419d-af68-6df1a75afb3f
relation.isAuthorOfPublication.latestForDiscoveryb1482a24-d9d8-419d-af68-6df1a75afb3f

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ART_Pilar Baylina.pdf
Size:
1.52 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESS - GAS - Artigos